CBIO logo

CRESCENT BIOPHARMA INC

CBIONASDAQ
🏆 #2926 by market capEarnings Nov 4US Equity
$782.40▼ $7.43 (−0.95%)
Simulated price
🔔
Track CBIO
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$540M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
100.0%
High
💵FCF Margin
-1292.8%
Thin
⚖️P/S Ratio
45.4x
Expensive
Otter Score
60
Fair
No chart data available for CBIO.

Trading Snapshot

Day Range
$774.64 – $789.51
52-Week Range
$8.72 – $27.41
Volume
$3.52B
Avg Volume
$2.61B
Shares Outstanding
37.1M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$12M
Last Q Revenue
$3M
P/E Ratio
-1.9
P/S Ratio
45.4x
EPS (TTM)
$-5.34
Dividend Yield
0.00%
Dilution (1yr)
+3028.0%

Why Investors Own CBIO

  • ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 75% gross margin and 28% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CBIO logo

CRESCENT BIOPHARMA INC

CBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$11M▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$153M▲ +205.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$144M▲ +364.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
20.2M▲ +3028.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$212M▲ +$201M YoY
StockOtter · stockotter.space

About CRESCENT BIOPHARMA INC

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$951.30
▲ +21.6% Upside
High Target$1,087.99
Low Target$850.83
Based on 20 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

CRESCENT BIOPHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift CBIO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

CRESCENT BIOPHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.